Restored nitric oxide bioavailability reduces the severity of acute-to-chronic transition in a mouse model of aristolochic acid nephropathy.
MouseChemical/toxinC57BL/6JMalen = n = 24 per group across four groups (96 mice); n = 8 per gr…Oral, in drinking water5% L-arginine in drinking water, an estimated intake of abo…Started 7 days before the first aristolochic acid injection
Model: Aristolochic acid nephropathy induced by daily intraperitoneal injection of aristolochic acid I at 3.5 mg/kg body weight for 4 days
L-arginine restored renal nitric oxide bioavailability and reduced tubular injury, inflammatory infiltration and interstitial fibrosis, lessening the severity of the acute-to-chronic transition, with the clearest functional benefit at day 10 and only partial prevention of polyuria at day 20.
Extraction: extract · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.